Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer
Autore:
Ducreux, N; Fizazi, K; Seitz, JF; Becouarn, Y; Armand, JP;
Indirizzi:
Inst Gustave Roussy, Gastroenterol Unit, F-94805 Villejuif, France Inst Gustave Roussy Villejuif France F-94805 , F-94805 Villejuif, France Inst Gustave Roussy, Dept Med, Villejuif, France Inst Gustave Roussy Villejuif France oussy, Dept Med, Villejuif, France CHU Timone, Marseille, France CHU Timone Marseille FranceCHU Timone, Marseille, France Fdn Bergonie, F-33076 Bordeaux, France Fdn Bergonie Bordeaux France F-33076 Bergonie, F-33076 Bordeaux, France
Titolo Testata:
BULLETIN DU CANCER
, volume: 88, anno: 2001,
pagine: S35 - S39
SICI:
0007-4551(200108)88:<S35:OICWNF>2.0.ZU;2-L
Fonte:
ISI
Lingua:
FRE
Soggetto:
LOW-DOSE LEUCOVORIN; RANDOMIZED TRIAL; CONTINUOUS-INFUSION; FLUOROURACIL BOLUS; PHASE-II; IRINOTECAN; CHEMOTHERAPY;
Keywords:
colorectal cancer; chimiotherapy; oxaliplatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Ducreux, N Inst Gustave Roussy, Gastroenterol Unit, Rue Camille Desmoulins, F-94805 Villejuif, France Inst Gustave Roussy Rue Camille Desmoulins Villejuif France F-94805
Citazione:
N. Ducreux et al., "Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer", B CANCER, 88, 2001, pp. S35-S39

Abstract

After decades of exclusive use of fluorouracil in the treatment of metastatic colorectal cancer, three new drugs, among them oxaliplatin, have recently shown interesting results. Oxaliplatin has an activity when it is given alone but this drug is particularly interesting for combination chemotherapy because it has a favourable toxicity, profile without important haematologic or digestive toxicities and because it has a convenient schedule of administration (short infusion every two or three weeks). Phases I and II studies have demonstrated the feasibility of the combination of raltitrexed andoxaliplatin. A recent phase II study has evaluated the efficacy of this new combination in 71 non pre-treated patients. The observed response rate was high: 59.5%. The combination of oxaliplatin and irinotecan has been assessed in three phase I studies (two with a three-weekly schedule and the lastone with a biweekly schedule). These studies have determined the doses which could he used in further phase II studies, these doses were close to thedoses used in monotherapy. Results of the efficacy of the three-weekly schedule are available only in second line therapy, with 42% of objective response rate in 36 patients. The dose intensity was maintained with the use ofhematopoietic growth factors. These new combinations with oxaliplatin giveus the opportunity to treat the patient with schedules excluding fluorouracil which has a variable metabolism.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 00:31:31